866-997-4948(US-Canada Toll Free)

Azilect Analysis and Estimates from 2005 to 2020

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 36 Pages


GlobalDatas pharmaceuticals report, Azilect Analysis and Estimates from 2005 to 2020 provides Azilect sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2005-2020). The report also includes information on Parkinson's Disease market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. 

Scope
  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Azilect including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Azilect including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2011-2020 for Azilect in each of the seven major markets
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 4
2.1 Parkinsons Disease 4
2.2 Symptoms of Parkinsons Disease 4
2.3 Diagnosis of Parkinsons disease 5
2.4 Parkinsons Disease Treatment Strategies 5
2.5 Parkinsons Disease Market 6
2.6 Epidemiology 6
2.7 Parkinsons Disease by Age and Gender 6
2.8 Etiology 7
2.9 GlobalData Report Guidance 7

3 Parkinsons Disease: Market Characterization 8
3.1 Parkinsons Disease Market 8
3.2 Parkinsons Disease Market Forecasts and CAGR 8
3.3 Factors Affecting Parkinsons Disease Market 9
3.3.1 High Prevalence: PD is the Second Most Frequent Neurodegenerative Disorder 9
3.3.2 Increase in Old Age Population 9
3.3.3 Patent Expiry of Prominent Drugs 9

4 Stages of Parkinsons Disease and Comparison of Treatments 10
4.1 The Hoehn and Yahr Scale 10
4.2 Modified Hoehn and Yahr Scale 10
4.3 The UPDRS 11

5 Staging of Parkinsons Disease 14
5.1 Distribution of Parkinsons disease Patients by Age Groups 14
5.2 Distribution of Patients by Stages 14

6 Azilect 15
6.1 Introduction 15
6.2 Mechanism of Action 15
6.3 Clinical Studies 15
6.3.1 Monotherapy 15
6.3.2 Adjunct to Levodopa 16
6.4 Approval History of Azilect 17
6.5 Factors Affecting Sales of Azilect 18
6.5.1 Used in Multiple Regimens 18
6.5.2 Unmet need 18
6.5.3 Better Safety Profile than Levodopa, Current SOC 18
6.5.4 Strong Patent Protection 18
6.5.5 Better presence in the market 18
6.5.6 Better Compliance 19
6.6 Drug Evaluation 19
6.6.1 Drug Risk Benefit Score 19
6.6.2 Intensity of Competition 20
6.7 Sales Estimates 21
6.7.1 Target Patient Pool of Azilect 21
6.7.2 Market Penetration 21
6.7.3 Dosing 22
6.7.4 Annual Cost of Therapy 22
6.7.5 Sales Estimates of Azilect 23

7 Parkinson Disease Market: Appendix 32
7.1 Market Definitions 32
7.2 List of Abberiviations 32
7.3 Research Methodology 32
7.3.1 Coverage 32
7.3.2 Secondary Research 33
7.3.3 Forecasting 33
7.3.4 Number of Patients Approved to take the Drug 33
7.3.5 Net Penetration of Drug 33
7.3.6 Net Annual Dosing 34
7.3.7 Annual Cost of Therapy 34
7.3.8 Primary Research 34
7.3.9 Expert Panels 35
7.4 Drug Sales Estimates Model 35
7.5 Contact Us 35
7.6 Disclaimer 35
7.7 Sources 36

List of Table


Table 1: Clinical Motor and Nonmotor Features of Parkinsons Disease 4
Table 2: Hoehn and Yahr Stages of Parkinsons Disease 10
Table 3: Hoehn and Yahr Stages of Parkinsons Disease 10
Table 4: Four Items, Part 1 of UPDRS 11
Table 5: Thirteen Items, Part 2 of Parkinsons disease 11
Table 6: Fourteen Items, Part 3 of UPDRS 12
Table 7: Fourteen Items, Part 3 of UPDRS 12
Table 8: Distribution of Parkinsons patients according to Hoehn and Yahr Classification 14
Table 9: UPDRS Score for Azilect as Monotherapy 15
Table 10: Change in Mean Total Daily OFF Time 16
Table 11: UPDRS ADL (Activities of Daily Living) Subscale Score while OFF 16
Table 12: UPDRS Motor Subscale Score while ON 16
Table 13: Approval History of Azilect 17
Table 14: Drug Risk Benefit Score (DRB)-Azilect 19
Table 15: Efficacy Comparison of Azilect 20
Table 16: Annual Cost of Azilect for Parkinsons Disease, 2011 22
Table 17: Azilect, Parkinsons Disease, Global, Sales Estimates ($m), 20052020 23
Table 18: Azilect, Parkinsons Disease, The US, Sales Estimates ($m), 20062020 24
Table 19: Azilect, Parkinsons Disease, UK, Sales Estimates ($m), 20052020 25
Table 20: Azilect, Parkinsons Disease, France, Sales Estimates ($m), 20062020 26
Table 21: Azilect, Parkinsons Disease, Germany, Sales Estimates ($m), 20052020 27
Table 22: Azilect, Parkinsons Disease, Italy, Sales Estimates ($m), 20072020 28
Table 23: Azilect, Parkinsons Disease, Spain, Sales Estimates ($m), 20062020 29
Table 24: Azilect, Parkinsons Disease, Japan, Sales Estimates ($m), 20062020 30

List of Chart


Figure 1: Current Pharmacologic Therapies for Parkinsons disease and Their Potential Sites of Action in the CNS 5
Figure 2: The Age-Specific Prevalence Rates of Parkinsons Disease in the Elderly Among Five European Countries, 2003 6
Figure 3: Parkinsons Disease, Global, Market Size Estimates ($bn), 20102020 8
Figure 4: Proportion of Population 60 Years or Older, World, 1950-2050 9
Figure 5: Points Distribution of UPDRS 13
Figure 6: Distribution of Parkinsons patients by Hoehn & Yahr Classification 14
Figure 7: Drug Model Diagram of Azilect in the US, EU and Japan 21
Figure 8: Azilect, Parkinsons Disease, Global, Sales Estimates ($m), 20052020 23
Figure 9: Azilect, Parkinsons Disease, The US, Sales Estimates ($m), 20062020 24
Figure 10: Azilect, Parkinsons Disease, The UK, Sales Estimates ($m), 20052020 25
Figure 11: Azilect, Parkinsons Disease, France, Sales Estimates ($m), 20062020 26
Figure 12: Azilect, Parkinsons Disease, Germany, Sales Estimates ($m), 20052020 27
Figure 13: Azilect, Parkinsons Disease, Italy, Sales Estimates ($m), 20072020 28
Figure 14: Azilect, Parkinsons Disease, Spain, Sales Estimates ($m), 20062020 29
Figure 15: Azilect, Parkinsons Disease, Japan, Sales Estimates ($m), 20062020 30
Figure 16: Azilect, Type 2 Diabetes, Sales Distribution by Country (%), 2016 31
Figure 17: Drug Model Diagram 34
Figure 18: Patients Approved for the Drug 34

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *